Valid HER2 testing is essential for optimal therapy of patients with HER2 positive gastric cancer and the correct use of first-line treatment. While each breast cancer is routinely being tested for the HER2 status, HER2 testing in gastric cancer has still not become part of the routine and is often only done upon request by the therapist. An interdisciplinary German expert group took the challenges of HER2 testing in gastric cancer as an opportunity to address essential aspects and questions for the practical use of HER2 testing in this indication from the perspective of pathologists and therapists. The recommendations made in this manuscript reflect the consensus of all participants and correspond to their opinions and long-term experience
Human epidermal growth factor receptor 2 (HER2) dysregulation is associated with tumorigenesis in ga...
Background. In gastric cancer (GC) the expression of HER2 is known as a marker of prognosis and rece...
HER2 gene amplification and receptor overexpression by tumors seems to be associated with poorer pro...
Valid HER2 testing is essential for optimal therapy of patients with HER2-positive gastric cancer an...
Valid HER2 testing is essential for the optimal care of patients with HER2-positive gastric cancer a...
Trastuzumab in combination with capecitabine or 5-fluorouracil and cisplatin is approved by the Euro...
As HER2 testing in gastric cancer is different from that in breast cancer, the Working Group Molecul...
Trastuzumab-based therapy has been shown to confer overall survival benefit in HER2-positive patient...
HER2 is overexpressed in approximately 10%-20% of gastric and gastroesophageal junction carcinomas. ...
Gastric cancer is one of the worldwide leading cancers which is highly prevalent in Eastern Asia. In...
Human epidermal growth factor receptor 2 (HER2) testing in gastric and gastroesophageal junction can...
HER2 (human epidermal growth factor receptor-2) assessment in histological samples of gastric cancer...
AIMS: Human epidermal growth factor receptor 2 (HER2) overexpression/amplification is implicated in ...
rastuzumab provides a survival benefit in patients with human epidermal growth factor receptor 2 (HE...
Trastuzumab provides a survival benefit in patients with human epidermal growth factor receptor 2 (H...
Human epidermal growth factor receptor 2 (HER2) dysregulation is associated with tumorigenesis in ga...
Background. In gastric cancer (GC) the expression of HER2 is known as a marker of prognosis and rece...
HER2 gene amplification and receptor overexpression by tumors seems to be associated with poorer pro...
Valid HER2 testing is essential for optimal therapy of patients with HER2-positive gastric cancer an...
Valid HER2 testing is essential for the optimal care of patients with HER2-positive gastric cancer a...
Trastuzumab in combination with capecitabine or 5-fluorouracil and cisplatin is approved by the Euro...
As HER2 testing in gastric cancer is different from that in breast cancer, the Working Group Molecul...
Trastuzumab-based therapy has been shown to confer overall survival benefit in HER2-positive patient...
HER2 is overexpressed in approximately 10%-20% of gastric and gastroesophageal junction carcinomas. ...
Gastric cancer is one of the worldwide leading cancers which is highly prevalent in Eastern Asia. In...
Human epidermal growth factor receptor 2 (HER2) testing in gastric and gastroesophageal junction can...
HER2 (human epidermal growth factor receptor-2) assessment in histological samples of gastric cancer...
AIMS: Human epidermal growth factor receptor 2 (HER2) overexpression/amplification is implicated in ...
rastuzumab provides a survival benefit in patients with human epidermal growth factor receptor 2 (HE...
Trastuzumab provides a survival benefit in patients with human epidermal growth factor receptor 2 (H...
Human epidermal growth factor receptor 2 (HER2) dysregulation is associated with tumorigenesis in ga...
Background. In gastric cancer (GC) the expression of HER2 is known as a marker of prognosis and rece...
HER2 gene amplification and receptor overexpression by tumors seems to be associated with poorer pro...